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To the editor: 
The absence of cellular immunity is central to the pathogenesis of herpesvirus-
mediated diseases after allogeneic hemopoietic stem cell transplantation 
(HSCT).1,2 For both bone marrow (BM)– and granulocyte-colony stimulating 
factor–mobilized peripheral blood stem cells (PBSCs) HSCT, donor-derived 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) peptide–specific CD8+ T 
cells clones undergo early expansion and persist long-term, with additional 
diversification arising from novel antigen-specific clones from donor-derived 
progenitors.3 Whether BM or PBSC is the superior source of antiviral CD8+ T cells 
is unclear. Given that PBSC has largely replaced BM as a source of stem cells for 
HSCT, it is unlikely that herpesvirus effector T-cell reconstitution will ever be 
compared prospectively. PBSC grafts contain 10 to 30 times more T cells than 
BM4 and a randomized study found proven viral infections were more frequent 
in BM than PBSC recipients,5 suggesting viral-specific T-cell immunity is 
enhanced in PBSC. Recently Moss showed in lung cancer patients that 
herpesvirus-specific BM-derived CD8+ T cells have unique homing properties 
relative to herpesvirus-specific CD8+ T cells present in unmobilized peripheral 
blood (PB).6 Immunodominant EBV-lytic peptide–specific CD8+ T cells were 
enriched in BM but were reduced for CMV peptide–specific CD8+ T cells relative 
to PB. EBV-latent peptide–specific CD8+ T cells were equivalent, which has 
relevance in the context of posttransplantation lymphoproliferative disorder for 
which impaired EBV-latent CD8+ T-cell immunity is a risk-factor.7 A comparison 
of herpesvirus-specific cellular immunity in PBSC versus PB has yet to be 
performed. 
 
We assayed the PBSC of 16 patients and the PB of 26 age-matched healthy 
volunteers. Although PBSC was obtained in patients and compared with PB of 
healthy subjects, our previous data indicate that CMV/EBV effector T-cell 
immunity is not impaired in these patients.8 The study had ethics approval and 
was conducted in accordance with the Declaration of Helsinki. In line with Moss 
in BM versus PB,6 CD8+ T cells were significantly increased and naive CD8+ T 
cells were reduced in PBSC relative to PB. Otherwise, CD8+ T-cell subsets in PBSC 
relative to PB were strikingly different compared with BM (Table 1). 
Undifferentiated CD8+ T cells (coexpressing the costimulatory molecules CD27 
and CD28) were reduced. In addition, CD8+ T cells expressing the lymphoid 
tissue homing molecule CD62L were lower which is consistent with recent 
mobilization of T cells from BM into the circulation. In keeping with this, we 
observed elevation of the chemokine receptors CXCR3 and CCR5 (markers of 
migratory effector T cells), but not CXCR6 (which facilitates egress into the lung, 
liver, and joints9), whereas in BM there is enrichment for 
CXCR3−CCR5+CXCR6+CD8+ T cells. As expected, the normal hierarchy of EBV lytic 
greater than latent T-cell responses seen in PB (P = .01) was preserved in PBSC 
(P = .03). Critically and in contrast to BM,6 in PBSC EBV-latent peptide–specific 
interferon-γ (IFN-γ) secreting CD3+CD8+ T cells were 20-fold lower than in PB 
(perhaps reflecting the lower EBV viral load in PBSC), whereas EBV-lytic and CMV 
peptide–specific IFN-γ CD8+ T cells were equivalent to PB. These results imply 
that within PBSC there is selective recruitment of CD8+ T-cell populations with a 
distinct functional and homing phenotype. In contrast to BM, EBV-latent but not 
CMV peptide–specific CD8+ T-cell immunity is impaired in PBSC relative to PB. 
The data have implications for HSCT and adoptive immunotherapy. 
 
Table 1  
Patient characteristics 
Characteristic 
PBSC PB 
P 
Findings of 
Moss in BM vs 
PB Median (range) SE 
Median 
(range) SE 
Age, y 66 (22-70) 3.713 
53 (24-
72) 2.79 NS  
Sex, M/F 11/5 NA 13/13 NA NS  
Diagnosis 
7 myeloma, 8 
lymphoma, 1 
Ewing sarcoma NA Healthy NA NA 
80% primary 
lung cancer, 
20% secondary 
lung cancer 
% CD3+CD8+ 40.9 3.329 27 1.8 **
  
CD4-CD8 ratio 1.288 0.213 2.358 0.2358 **
 
Increased CD8+ 
(NS) 
Characteristic 
PBSC PB 
P 
Findings of 
Moss in BM vs 
PB Median (range) SE 
Median 
(range) SE 
% CD8+CD45RAhiCCR7+ 
(naive) 20.56 2.774 50.3 2.354 ***
 
Lower in BM 
% CD8+CD45RAloCCR7+ 
(CM) 20.96 3.54 10.2 1.11 *
 
Equivalent 
CD8+CD45RAloCCR7− 
(EM) 16 3.196 17.3 1.571 NS Higher in BM 
% CD8+CD45RAhiCCR7− 
(EMR) 19.2 2.589 20 1.16 NS Lower in BM 
% CD8+CD62L 14.81 1.615 36.75 24.452 ***
 
Higher in BM 
% CD8+27+28+ 33.7 5.581 57.75 3.181 *
 
Higher in BM 
% CD8+27−28+ 17.1 2.313 7.55 1.157 ***
 
Equivalent 
% CD8+27+28− 10.19 1.187 18.8 1.862 ***
 
Equivalent 
% CD8+27−28− 30.45 4.818 23.45 3.226 NS Lower in BM 
% CD8+CXCR3+ 2.16 0.67 0.775 0.165 *
 
Lower in BM 
% CD8+CCR5+ 31 3.746 25.13 1.586 *
 
Higher in BM 
% CD8+CXCR6+ 4.745 0.92 2.55 0.53 NS Higher in BM 
% FOXP3+CD4+ 5.35 0.87 6.772 0.54 NS  
% EBV latent peptide–
specific IFN-γ 
CD3+CD8+ 0.01 0.1114 0.2 0.5901 *
 
Equivalent 
% EBV lytic peptide–
specific IFN-γ 
CD3+CD8+ 0.605 0.461 1.64 0.984 NS Higher in BM 
% CMV peptide–specific 
IFN-γ CD3+CD8+ 0.25 0.123 0.59 0.6653 NS Lower in BM 
Characteristic 
PBSC PB 
P 
Findings of 
Moss in BM vs 
PB Median (range) SE 
Median 
(range) SE 
EBV-DNA copies/106 
cells 0 (0-42) 2.871 
2685 
(0-
3614) 251.9 **
 
Lower in BM 
 Herpesvirus peptide–specific IFN-γ producing CD8+ T cells were detected by 
intracellular cytokine staining by stimulating PB or PBSCs with appropriate HLA 
class I–restricted viral peptide as previously described.8 Intravenous 
cyclophosphamide (2 g/m2) and subcutaneous G-CSF (10 mcg/kg) were used 
for PBSC mobilization. Leukapheresis was performed using a Cobe Spectra 
Gambro BCT continuous flow cell separator. 
 PBSC indicates peripheral blood stem cells; PB, peripheral blood; BM, bone 
marrow; NS, not significant; NA, not applicable; IFN-γ, interferon-γ; CM, 
central memory; EM, effector memory; and EMR, effector memory revertant. 
 ↵* P = .05-.01; 
 ↵** P = .01-.001; 
 ↵*** P < .001. 
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